144 related articles for article (PubMed ID: 11698699)
1. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.
Brumme ZL; Chan KJ; Dong W; Hogg R; O'Shaughnessy MV; Montaner JS; Harrigan PR
AIDS; 2001 Nov; 15(17):2259-66. PubMed ID: 11698699
[TBL] [Abstract][Full Text] [Related]
2. CCR5 genotype and pre-treatment CD4+ T-cell count influence immunological recovery of HIV-positive patients during antiretroviral therapy.
Carvalho-Silva WHV; Andrade-Santos JL; Guedes MCDS; Crovella S; Guimarães RL
Gene; 2020 May; 741():144568. PubMed ID: 32165289
[TBL] [Abstract][Full Text] [Related]
3. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
[TBL] [Abstract][Full Text] [Related]
4. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
5. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.
Brumme ZL; Dong WW; Chan KJ; Hogg RS; Montaner JS; O'Shaughnessy MV; Harrigan PR
AIDS; 2003 Jan; 17(2):201-8. PubMed ID: 12545080
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
O'Brien TR; McDermott DH; Ioannidis JP; Carrington M; Murphy PM; Havlir DV; Richman DD
AIDS; 2000 May; 14(7):821-6. PubMed ID: 10839590
[TBL] [Abstract][Full Text] [Related]
7. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts.
Puissant B; Roubinet F; Massip P; Sandres-Saune K; Apoil PA; Abbal M; Pasquier C; Izopet J; Blancher A
AIDS Res Hum Retroviruses; 2006 Feb; 22(2):153-62. PubMed ID: 16478397
[TBL] [Abstract][Full Text] [Related]
8. No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.
Brumme ZL; Chan KJ; Dong WW; Mo T; Wynhoven B; Hogg RS; Montaner JS; O'Shaughnessy MV; Harrigan PR
AIDS; 2002 Sep; 16(14):1929-33. PubMed ID: 12351953
[TBL] [Abstract][Full Text] [Related]
9. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type.
Bogner JR; Lutz B; Klein HG; Pollerer C; Troendle U; Goebel FD
HIV Med; 2004 Jul; 5(4):264-72. PubMed ID: 15236615
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort.
Eugen-Olsen J; Iversen AK; Benfield TL; Koppelhus U; Garred P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):110-6. PubMed ID: 9637575
[TBL] [Abstract][Full Text] [Related]
11. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children.
Ometto L; Bertorelle R; Mainardi M; Zanchetta M; Tognazzo S; Rampon O; Ruga E; Chieco-Bianchi L; De Rossi A
J Infect Dis; 2001 Mar; 183(5):814-8. PubMed ID: 11181160
[TBL] [Abstract][Full Text] [Related]
13. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
14. The Frequency of CCR5del32 Mutation in Populations of Russians, Tatars and Bashkirs of Chelyabinsk Region, Russia.
Govorovskaya I; Khromova E; Suslova T; Alexeev L; Kofiadi I
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):109-112. PubMed ID: 28083604
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
[TBL] [Abstract][Full Text] [Related]
16. IL18 gene polymorphism and its influence on CD4+ T-cell recovery in HIV-positive patients receiving antiretroviral therapy.
Andrade-Santos JL; Carvalho-Silva WHV; Coelho AVC; Souto FO; Crovella S; Brandão LAC; Guimarães RL
Infect Genet Evol; 2019 Nov; 75():103997. PubMed ID: 31401307
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
18. CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.
Jin Q; Agrawal L; Meyer L; Tubiana R; Theodorou I; Alkhatib G
J Virol; 2008 Mar; 82(5):2418-26. PubMed ID: 18094161
[TBL] [Abstract][Full Text] [Related]
19. Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.
Ruiz-Mateos E; Tarancon-Diez L; Alvarez-Rios AI; Dominguez-Molina B; Genebat M; Pulido I; Abad MA; Muñoz-Fernandez MA; Leal M
Antiviral Res; 2018 Feb; 150():15-19. PubMed ID: 29221798
[TBL] [Abstract][Full Text] [Related]
20. Human CCR5Δ32 (rs333) polymorphism has no influence on severity and mortality of influenza A(H1N1)pdm09 infection in Brazilian patients from the post pandemic period.
Matos AR; Martins JSCC; Oliveira MLA; Garcia CC; Siqueira MM
Infect Genet Evol; 2019 Jan; 67():55-59. PubMed ID: 30389547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
